author-photo

Suman Redhu

Novartis

11

Papers

176

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.

2020 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (9)
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data

2018 BMJ Open
Show All
- Source
- Cite
- Save
Citations (1)
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

2017 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (11)
Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
101PAssociation between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (134)
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

2015 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (5)